top of page

Aromatase Inhibitors: Hormone Therapy for Breast Cancer

Sep 28
6 min read

Updated: Nov 11

Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026

Editorial note: This article is for general education only. It is not medical advice, a diagnosis, or a treatment plan. Always consult a qualified healthcare professional for personal medical decisions.

Quick Answer: How Do Aromatase Inhibitors Work?

Aromatase inhibitors work by blocking the aromatase enzyme, which converts other hormones into estrogen. [2] They are used for estrogen receptor-positive breast cancer, where estrogen fuels tumor growth. [1] These daily pills lower the risk of cancer returning after surgery. [2] Most patients take them for five years, and studies show a 40% reduction in breast cancer mortality over ten years. [2] [4]

What the research says

  • Aromatase inhibitors save more lives than tamoxifen after menopause. Pooling trials of 31,920 postmenopausal women with hormone-sensitive early breast cancer, 5 years of an aromatase inhibitor lowered 10-year breast cancer deaths to 12.1%, vs 14.2% with 5 years of tamoxifen. Aromatase inhibitors caused fewer womb cancers (0.4% vs 1.2%) but more bone fractures (8.2% vs 5.5% over 5 years) (Early Breast Cancer Trialists' Collaborative Group, The Lancet, 2015). [4]

  • Taking them for 10 years further cuts recurrence, at a cost to bones. In 1,918 women who had already taken an aromatase inhibitor, 5 more years of letrozole raised 5-year disease-free survival to 95% vs 91% with placebo and lowered cancer in the other breast. Overall survival was not improved, and bone pain, fractures and osteoporosis were more common (Goss et al., The New England Journal of Medicine, 2016). [5]

What are aromatase inhibitors?

Aromatase inhibitors are a cornerstone of hormone therapy for people diagnosed with estrogen receptor-positive (ER+) breast cancer. This type of cancer is made up of cells that use the hormone estrogen as a primary fuel for growth and replication. [1] Because ER-positive breast cancer frequently affects postmenopausal females over the age of 50, aromatase inhibitors are a standard treatment for this group. The therapy aims to minimize estrogen in the body to slow the progression or return of the disease.

How does aromatase inhibitor therapy work?

Aromatase inhibitors target the aromatase enzyme, which is responsible for converting other hormones in the body into estrogen. [2] In postmenopausal individuals, the ovaries no longer produce estrogen; instead, the hormone is made mainly in fat tissue and other areas through the aromatase process. [3] By blocking this enzyme, aromatase inhibitors “starve” any remaining cancer cells of the estrogen they need to survive. This whole-body approach helps manage the disease even if it has spread to other parts of the body.

Aromatase inhibitor mechanism: the drug blocks the aromatase enzyme so androgens are not converted into estrogen – rinnit.com

Figure 1: Aromatase inhibitors block the aromatase enzyme, preventing androgens from being converted into estrogen.

When Are Aromatase Inhibitors Used?

  • After surgery: to reduce the risk of cancer recurrence after the initial cancer is removed. [1] [2]

  • Metastatic cancer: to manage cancer that has spread to organs such as the lungs or bones. [1]

  • Lymph node involvement: to treat ER-positive cancer found in nearby lymph nodes.

  • Preventative use (off-label): to reduce risk in people with a high predisposition to breast cancer.

What are the common aromatase inhibitors, and how are they taken?

Three aromatase inhibitor medications are used in clinical practice, all given as daily oral pills. [2] Depending on the case, a healthcare provider may prescribe an aromatase inhibitor as the first line of hormone therapy or switch a patient to one after several years of tamoxifen. [1] [2] Consistency matters, because even small amounts of estrogen can influence cancer cell behavior.

  • Letrozole: often used after surgery or after tamoxifen therapy.

  • Anastrozole: a standard daily pill for postmenopausal ER+ breast cancer.

  • Exemestane: frequently prescribed to reduce recurrence risk.

How long does aromatase inhibitor treatment last, and how successful is it?

The standard duration is typically five years, although some patients continue longer based on their risk profile. [2] Research indicates that approximately 95% of individuals who complete treatment after surgery remain cancer-free five years later. Long-term studies also show that patients using these medications have a 40% lower risk of dying from breast cancer over ten years compared with those who do not receive hormone-blocking therapy. [4]

What are the side effects of aromatase inhibitors, and how are they managed?

Aromatase inhibitors can be life-saving, but because estrogen plays a protective role in other body systems such as bone and heart health, they can cause side effects. Common ones include joint and muscle pain, hot flashes, and vaginal dryness. More seriously, lower estrogen can decrease bone density, increasing the risk of osteoporosis and fractures [4] [5], and there is an increased risk of cardiovascular disease while on therapy. Patients are encouraged to monitor their bone health and discuss management strategies with their providers, such as switching medications or using anti-inflammatory drugs.

Managing aromatase inhibitor side effects: bone health, joint pain, and heart health tips – rinnit.com

Figure 2: Practical steps for protecting bone health, easing joint pain, and supporting heart health during aromatase inhibitor therapy.

What are recovery and the long-term outlook with aromatase inhibitors?

The outlook for patients on aromatase inhibitors is generally positive, provided side effects are managed well enough to keep taking the medication. Because breast cancer can return many years after initial treatment — sometimes up to 20 years later — regular follow-ups and monitoring are essential. Report any new symptoms or severe side effects to your medical team right away. With proper care, most people can complete the five-year course and significantly improve their long-term survival prospects.

Comparison of breast cancer outcomes with and without aromatase inhibitor therapy – rinnit.com

Figure 3: Aromatase inhibitor therapy is associated with reduced mortality and recurrence compared with no hormone-blocking therapy.

What are the next steps if you are prescribed aromatase inhibitors?

If you have been prescribed an aromatase inhibitor, begin by discussing a long-term monitoring plan with your oncologist, including regular bone density scans and cardiovascular health checks. Set up a routine for taking your daily pill so no doses are missed. If joint pain or other side effects interfere with daily life, speak with your provider about adjustment options early so you can stay on the medication for the full recommended duration.

Key Takeaways

  • Aromatase inhibitors block the enzyme that makes estrogen, starving ER-positive breast cancer cells of the hormone they need.

  • The three main drugs are letrozole, anastrozole, and exemestane, taken as a daily pill, usually for five years.

  • About 95% of people who complete treatment after surgery are cancer-free at five years, with a 40% lower risk of breast cancer death over ten years.

  • Joint pain, hot flashes, vaginal dryness, bone loss, and cardiovascular risk are the main side effects to manage.

  • Late recurrence can occur up to 20 years later, so long-term follow-up matters.

Related Reading

Frequently Asked Questions

What are aromatase inhibitors?

Aromatase inhibitors are hormone therapy drugs that lower estrogen levels to treat ER-positive breast cancer.

Who should take these medications?

Aromatase inhibitors are primarily prescribed for postmenopausal individuals with estrogen receptor-positive breast cancer. They do not work on their own while the ovaries are still active, so premenopausal patients take them only together with treatment that stops ovarian estrogen production.

How do they work?

Aromatase inhibitors block the aromatase enzyme, which prevents the body from converting other hormones into estrogen.

What are the most common aromatase inhibitors?

The three most common are letrozole, anastrozole, and exemestane.

How long is the treatment?

Most patients take these daily pills for five years, and some continue longer depending on their risk profile.

Can males take aromatase inhibitors?

Yes. They are used for males with ER-positive breast cancer, often with additional therapy.

What is the success rate?

About 95% of patients remain cancer-free five years after completing treatment following surgery.

Do these drugs prevent cancer?

Aromatase inhibitors can reduce risk in people with a high predisposition to breast cancer, but they are not FDA-approved for general prevention.

What are the side effects on bones?

Aromatase inhibitors can decrease bone density, increasing the risk of osteoporosis and fractures. Regular bone density scans are recommended.

How is joint pain managed?

Providers may suggest NSAIDs, switching to a different aromatase inhibitor, or substituting tamoxifen.

Do they cause hot flashes?

Yes. Hot flashes and vaginal dryness are common side effects because estrogen levels are lowered.

Can I switch from tamoxifen to an aromatase inhibitor?

Yes. Many patients take tamoxifen for a few years before switching to an aromatase inhibitor.

Is cardiovascular health affected?

Yes. There is an increased risk of cardiovascular disease while on this therapy, so regular cardiovascular check-ups are advised.

When should I call my doctor?

Call if side effects are severe or if you notice symptoms that could indicate a cancer recurrence.

What is late recurrence?

Late recurrence refers to breast cancer returning up to 20 years after treatment, which is why long-term monitoring is important.

References

  1. National Cancer Institute. Hormone Therapy for Breast Cancer. National Cancer Institute. Updated September 23, 2026. https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet

  2. DePolo J. Aromatase Inhibitors: Benefits, Side Effects, and More. Breastcancer.org. Updated April 15, 2026. https://www.breastcancer.org/treatment/hormonal-therapy/aromatase-inhibitors

  3. American Cancer Society. Hormone Therapy for Breast Cancer. American Cancer Society. Accessed October 14, 2026. https://www.cancer.org/cancer/types/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html

  4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet. 2015;386(10001):1341-1352. PMID 26211827. https://doi.org/10.1016/S0140-6736(15)61074-1

  5. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. The New England Journal of Medicine. 2016;375(3):209-219. PMID 27264120. https://doi.org/10.1056/NEJMoa1604700

  6. Cleveland Clinic. Aromatase Inhibitors for Breast Cancer. Cleveland Clinic. Last updated October 8, 2026. https://my.clevelandclinic.org/health/treatments/24685-aromatase-inhibitors

Medical disclaimer

Medical disclaimer: The information provided in this article is for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Comments


Spotted an error or a dead link? Tell us

 

Want another health topic explained?

bottom of page